title: Podophyllin office therapy against condyloma should be abandoned.
abstract: Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin-the purified, standardised active antiwart ingredient of podophyllin-represents safe and effective first line therapy for patients with anogenital warts.
authors.affiliation: Department of Dermatovenereology, Karolinska Hospital, 17176, Stockholm, Sweden. geo.von.krogh@ood.ki.se
authors.forename: G
authors.initials: G
authors.lastname: von Krogh
authors.forename: E
authors.initials: E
authors.lastname: Longstaff
mesh_terms: D003218:Condylomata Acuminata / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010789:Phototherapy / Q000009:adverse effects*; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use; D011033:Podophyllin / Q000009:adverse effects* / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007641:Keratolytic Agents; D010936:Plant Extracts; D011033:Podophyllin; D011034:Podophyllotoxin